Syros Pharmaceuticals, Inc.

NasdaqGS:SYRS Stock Report

Market Cap: US$163.1m

Syros Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Syros Pharmaceuticals's earnings have been declining at an average annual rate of -10.7%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been growing at an average rate of 31.4% per year.

Key information

-10.7%

Earnings growth rate

18.6%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate31.4%
Return on equity-289.1%
Net Margin-1,193.3%
Next Earnings Update27 Mar 2024

Recent past performance updates

Recent updates

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Jan 14

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Sep 20

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Sep 13

Syros Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Syros Pharmaceuticals Is A Buy As New Trials Start

Nov 20

Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 08
Syros Pharmaceuticals (NASDAQ:SYRS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 02
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year

Syros Pharma up 18% day after ARK Innovation dumps shares

May 27

Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

May 11
Analysts Just Made A Substantial Upgrade To Their Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Forecasts

Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

May 07
Does Syros Pharmaceuticals (NASDAQ:SYRS) Have A Healthy Balance Sheet?

Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

Mar 02
Can You Imagine How Syros Pharmaceuticals' (NASDAQ:SYRS) Shareholders Feel About The 57% Share Price Increase?

What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Jan 26
What Kind Of Investors Own Most Of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)?

Syros Pharmaceuticals After The Orsenix Deal

Dec 29

Revenue & Expenses Breakdown
Beta

How Syros Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SYRS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 239-10530112
30 Jun 239-9530112
31 Mar 2312-9330116
31 Dec 2215-9529112
30 Sep 2223-1142827
30 Jun 2225-10926112
31 Mar 2224-9724105
31 Dec 2123-8723100
30 Sep 2121-9322102
30 Jun 2120-862293
31 Mar 2118-812282
31 Dec 2015-842176
30 Sep 2010-742261
30 Jun 207-742260
31 Mar 204-762260
31 Dec 192-752158
30 Sep 192-741959
30 Jun 192-701856
31 Mar 192-641752
31 Dec 182-621650
30 Sep 181-601647
30 Jun 181-581544
31 Mar 180-571543
31 Dec 171-541442
30 Sep 171-501339
30 Jun 171-501240
31 Mar 171-511139
31 Dec 160-511038
30 Sep 160-521038
30 Jun 160-48933
31 Mar 160-41729
31 Dec 150-35624
30 Sep 150-28419
31 Dec 140-16311

Quality Earnings: SYRS is currently unprofitable.

Growing Profit Margin: SYRS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SYRS is unprofitable, and losses have increased over the past 5 years at a rate of 10.7% per year.

Accelerating Growth: Unable to compare SYRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SYRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: SYRS has a negative Return on Equity (-289.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.